Orasis Submits NDA for Blurry Vision Treatment
If approved, CSF-1 would be the second therapy to treat patients with presbyopia, or age-related blurry vision.
Orasis Pharmaceuticals has submitted a new drug application (NDA) to the FDA for investigational CSF-1 to treat people with presbyopia, or age-related blurry vision. CSF-1 is a preservative-free formulation of low-dose pilocarpine administered as an eye drop.
Presbyopia is the loss of ability to focus on near objects as a result of the natural aging process. It occurs mostly after the age of 40 when the crystalline lens of the eye gradually stiffens and loses flexibility.
If approved, this would be the second therapy to treat patients with presbyopia. The first FDA- approved therapy is Vuity, which was developed by Allergan, an AbbVie company. Vuity is a daily, prescription eye drop that works lasts up to 6 hours. Vuity uses a technology allows the therapy to rapidly adjust to the physiologic pH of the tear film. The wholesale acquisition cost (WAC), for one bottle of Vuity is $73.49
Elad Kedar
“With more than 120 million people in the United States affected, we look forward to working with the FDA during its review process to ultimately provide an alternative treatment option for patients seeking flexibility in managing their presbyopia,” Elad Kedar, chief executive officer of Orasis Pharmaceuticals, said in a press release.
Related: Therapy for Blurry Vision Shows Positive Results
The NDA is based on data from the phase 3 NEAR-1 and NEAR-2 clinical trials, involving more than 600 patients. Both trials met their primary and key secondary endpoints on day 8, achieving statistically significant three-line or more gain in distance-corrected near visual acuity (DCNVA), and no loss of one-line or more in distance visual acuity.
The most common treatment-related adverse events of headache and instillation site pain occurred in only 6.8% and 5.8% of participants, respectively. Of all CSF-1 participants, only 2.6% reported moderate treatment-related adverse events. All other adverse events were mild.
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
